Correlation Between Minimal Secretory Capacity of Pancreatic β-Cells and Stability of Diabetic Control

The significance of the minimal secretory capacity of pancreatic β-cells for the stability of the plasma glucose level was studied in 20 patients with insulin-dependent diabetes mellitus. Changes in plasma concentrations of major counterregulatory hormones in response to hypoglycemia were also investigated in these patients to clarify their contribution to diabetic brittleness. β-Cell function was evaluated on the basis of elevation of plasma C-peptide immunoreactivity (CPR) during the intravenous glucagon test with a highly sensitive assay for plasma CPR that could detect as little as 0.03 ng/ml. After stimulation with glucagon, a significant increase in plasma CPR was observed in 10 of the patients whose β-cell function had been evaluated as completely depleted by a conventional assay for plasma CPR. A clear inverse correlation was found between the secretory capacity of pancreatic β-cells measured in this way and the degree of glycemic instability (r = −.74, P < .01). Infusion of insulin at a rate of 0.15 U.kg−1.h−1 for 60 min caused a continuous decrease in the plasma glucose level, resulting in neuroglycopenia in 7 of the 10 CPR nonresponders but only 2 of the CPR responders. During insulin-induced hypoglycemia, plasma glucagon immunoreactivity did not increase in the CPR nonresponders but increased significantly in the CPR responders. A positive correlation was found between the minimal residual β-cell capacity and the responsiveness of α-cells to hypoglycemia (r = .65, P < .01).In contrast to the difference in the responses of their pancreatic α-cells to hypoglycemia, the two groups showed more or less the same responses of plasma epinephrine, norepinephrine, growth hormone, and cortisol to hypoglycemia. Total lack of insulinogenic reserve inevitably results in loss of automatic regulation of the circulating insulin level and seems to be a major factor in causing hyperlability of diabetic control. The lack of β-cell function may be related causally to pancreatic α-cell dysfunction, which also contributes in part to metabolic variability in brittle diabetes.

[1]  C. Christiansen,et al.  Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. , 2009, Acta medica Scandinavica.

[2]  R. Puukka,et al.  Residual B-Cell Function and Glycaemic Control in Diabetic Pregnancy , 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[3]  G. Bolli,et al.  Simulation of the normal glucopenia-induced decline in insulin partially restores the glucagon response to glucopenia in isolated perfused pancreata of streptozotocin-diabetic rats. , 1986, Endocrinology.

[4]  P. Cryer,et al.  Plasma Pancreatic Polypeptide Response to Insulin-induced Hypoglycemia as a Marker for Defective Glucose Counterregulation in Insulin-dependent Diabetes Mellitus , 1985, Diabetes.

[5]  L. Orci,et al.  Adrenergically mediated intrapancreatic control of the glucagon response to glucopenia in the isolated rat pancreas. , 1985, The Journal of clinical investigation.

[6]  B. Thorsteinsson,et al.  The C-Peptide Response to Glucagon Injection in IDDM and NIDDM Patients , 1985, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  L. Orci,et al.  Insulin within islets is a physiologic glucagon release inhibitor. , 1984, The Journal of clinical investigation.

[8]  T. Hanafusa,et al.  Decreased Response of Epinephrine and Norepinephrine to Insulin-Induced Hypoglycemia in Diabetic Autonomic Neuropathy , 1984, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[9]  P. Cryer,et al.  Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. , 1984, The New England journal of medicine.

[10]  H. Shamoon,et al.  Impaired Counterregulation of Hypoglycemia in Insulin-dependent Diabetes Mellitus , 1983, Diabetes.

[11]  R. Unger.  Insulin-Glucagon Relationships in the Defense Against Hypoglycemia , 1983, Diabetes.

[12]  P. Cryer,et al.  Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. , 1983, The New England journal of medicine.

[13]  R. Hoeldtke,et al.  Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones. , 1981, The New England journal of medicine.

[14]  N. Yanaihara,et al.  Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment. , 1981, Clinical chemistry.

[15]  P. Cryer.  Glucose Counterregulation in Man , 1981, Diabetes.

[16]  C. Christiansen,et al.  Beta-cell function and metabolic control in insulin treated diabetics. , 1980, Acta endocrinologica.

[17]  Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.

[18]  C. Kawai,et al.  Ultramicro method for the determination of picogram amounts of norepinephrine and epinephrine by high-performance liquid chromatography. , 1979, Journal of chromatography.

[19]  R. Goldberg,et al.  Metabolic Control in Diabetic Patients: Effect of Insulin-secretory Reserve (Measured by Plasma C-Peptide Levels) and Circulating Insulin Antibodies , 1979, Diabetes.

[20]  R. Rizza,et al.  Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. , 1979, The Journal of clinical investigation.

[21]  S. Tarui,et al.  Studies on the Etiology of “Brittle Diabetes”: Relationship Between Diabetic Instability and Insulinogenic Reserve , 1977, Diabetes.

[22]  O. Faber,et al.  C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus , 1977, Diabetes.

[23]  W. F. Taylor,et al.  Abnormalities of Endogenous Glucagon and Insulin in Unstable Diabetes , 1977, Diabetes.

[24]  S. Tarui,et al.  Effect of an exposure to chloramine-T on the immunoreactivity of glucagon. , 1975, Endocrinology.

[25]  H. Oka,et al.  Radioimmunoassay of human proinsulin C-peptide using synthetic human connecting peptide. , 1974, Endocrinologia japonica.

[26]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.

[27]  K. Mashimo,et al.  A Simple Method for the Determination of Serum Free Insulin Levels in Insulin-treated Patients , 1973, Diabetes.

[28]  J. Palmer,et al.  Glucose counterregulation during recovery from neuroglucopenia: which mechanism is important? , 1985, Metabolism: clinical and experimental.

[29]  B. Beck,et al.  C-peptide comparative radioimmunoassays: a study of three commercial kits. , 1983, Annales de Biologie Clinique.

[30]  R. Baxter,et al.  C-peptide secretion and insulin antibodies as determinants of stability in diabetes mellitus. , 1978, Metabolism: clinical and experimental.

[31]  R. Pildes,et al.  Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity. , 1977, Jornal de Pediatria.